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A b o u t  H e p p
HEPP News, a forum for correctional
problem solving, targets correctional
administrators and HIV/AIDS care
providers including physicians, nurses,
outreach workers, and case managers.
Published monthly and distributed by fax,
HEPP News provides up-to-the-moment
information on HIV treatment, efficient
approaches to administering HIV treatment
in the correctional environment, national
and international news related to HIV in
prisons and jails, and changes in correc-
tional care that impact HIV treatment.
Continuing Medical Education credits are
provided by the Brown University Office of
Continuing Medical Education to physi-
cians who accurately respond to the ques-
tions on the last page of the newsletter.  
The editorial board and contributors to
HEPP News include national and regional
correctional professionals, selected on the
basis of their experience with HIV care in
the correctional setting and their familiarity
with current HIV treatment. We encourage
submissions, feedback, and correspon-
dence from our readership.  The goal of
HEPP News is to provide our readers with
reports of effective and cost-conscious HIV
care that can truly be implemented with the
correctional environment.  We hope our
newsletter achieves that goal.
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Managing HIV Care in a Large State System - Texas 
David Paar, M.D.
Assistant Professor of Medicine
Division of Infectious Diseases
Director, AIDS Care and Clinical Research Program
(ACCRP)
The University of Texas Medical Branch at Galveston
Speakers Bureau: Roche Pharmaceuticals. Grant & Research
Support: Merck, Roche, Pfizer, Glaxo Wellcome, Immune
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With an area of 267,277 square miles and a pop-
ulation of 18.7 million inhabitants, Texas is the sec-
ond largest and second most populous state in the
U.S.  The combination of multiple, large cities with
attendant inner city conditions predisposed to high
rates of HIV infection (socioeconomic impoverish-
ment, low educational levels, illicit drug use) and a
racially and ethnically diverse population dispro-
portionately affected by the U.S. HIV epidemic,
account for a large HIV positive population in
Texas jails and prisons.  It follows that Texas pris-
oner populations have the fourth highest AIDS
prevalence rate in the nation (1876 HIV or AIDS
cases reported in 1996)(1).
HIV in TDCJ
The Texas Department of Criminal Justice (TDCJ)
is responsible for correctional custody of "offend-
ers", the preferred designation for Texas state
inmates.  Texas has the second largest incarcer-
ated population in the U.S. (an estimated 135,407
offenders in TDCJ facilities and an additional
15,000 - 16,000 offenders who are housed in pri-
vate correctional facilities)(2).  Texas offenders
diagnosed with chronic medical conditions are
assigned to TDCJ facilities rather than to private
correctional facilities, so that chronic care can be
provided by a managed health care system.
Several independent managed healthcare con-
tracts provide pharmacy services and medical
care.  Under these contracts each TDCJ facility
has its own primary care health care delivery sys-
tem which may be staffed by physicians, dentists,
optometrists, mid-level practitioners (physician
assistants, clinical pharmacists, nurse practition-
ers), Certified Medication Aids (CMAs), nurses,
laboratory personnel, and other ancillary health
care personnel.  In contrast, outpatient specialty
health care as well as inpatient hospitalization
occurs at facilities located on Texas Tech and
UTMB Galveston campuses.  
With regard to Medical Care, the state is divided
into eastern and western halves that are approxi-
mately equal in area, but unequal in terms of
TDCJ offender population.  University of Texas
Medical Branch Galveston is responsible for the
eastern half of the state, which houses approxi-
mately 104,264 offenders inCJ units. Virtually all
HIV positive offenders are assigned to units in the
eastern half of the state, which means UTMB pro-
vides CJ units. Virtually all HIV positive offenders
are assigned to units in the eastern half of the
state, which means UTMB provides nearly all of
the HIV health care for TDCJ.  Given the number
of offenders in TDCJ, medical health care and
pharmacy budgets are enormous.  Delivery of ser-
vices must be efficient in order to derive maximum
benefit from these health care dollars (see Table 1
on page 2).   
HIV Care Management
The HIV-Specific Infection Control Policy, devel-
oped and periodically updated by the TDCJ Office
of Preventive Medicine in Huntsville, Texas,
serves as a guideline for HIV health care and is
reflective of local standards of HIV health care.
The policy is comprehensive and covers a variety
of HIV-related issues including the method of HIV
testing offered, referral of HIV positive offenders
for specialty care, baseline and follow-up clinical
and laboratory evaluations, schedule of vaccine
administration and periodic HIV-related health
screening (PPD, pelvic examinations, retinal
exams, etc.), initiation of prophylactic therapies to
reduce the incidence of opportunistic infections,
and initiation of antiretroviral therapy. 
Testing
As of May 1998, TDCJ has offered "routine HIV
testing" to offenders.  Routine testing  means that
an HIV test is conducted, unless the offender
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refuses, for offenders:•
*who report a past history of HIV infec-
tion, hemophilia, or a history of high
risk behaviors for acquiring HIV infec-
tion;  
*for whom live virus immunization is
planned; 
*who have psychiatric disorders or dis-
play symptoms possibly consistent
with AIDS-related dementia; and 
*who have certain indicator conditions
(TB infection or disease, any sexually
transmitted disease, cervical dyspla-
sia, Hepatitis B and C infections). 
Routine testing is performed at entry into the
TDCJ and yearly thereafter.  Verbal consent is
required before HIV testing is performed and all
tested offenders receive pre- and post-test coun-
seling.  Prior to May 1998, HIV testing was
offered on a voluntary basis (see Tables 2 and 3
below).
The Treatment System
The Infection Control Policy specifies that TDCJ
offenders with HIV infection must be evaluated
and treated by a physician with expertise in HIV
health care.  As a result of recent endeavors to
unify UTMB Galveston HIV Health Care and
Unit-Based HIV Health Care, clinic visits at the
two locations are linked so that offenders do not
have to be transported as frequently as in the
past, when Specialty Health Care and Unit-
Based Health Care were isolated from one
another.  The current Infection Control Policy
also specifies CID nurse visits every 60 days for
HIV positive offenders.  
The Infection Control Policy for vaccine adminis-
tration, HIV-related periodic health screening,
and initiation of prophylactic therapies are based
on nationally published guidelines (1999
USPHS/IDSA Guidelines for the Prevention of
Opportunistic Infections in Persons Infected with
Human Immunodeficiency Virus available at:  
http://aepo-xdv-www.epo.cdc.gov/wonder/
PrevGuid/m0048226/m0048226.htm.  Similarly,
initiation of antiretroviral therapy is based on
nationally published guidelines (Report of the
NIH Panel to Define Principles of Therapy for
HIV Infection and Guidelines for the Use of
Antiretroviral Agents in HIV-Infected Adults and
Adolescents available at: http://text.nlm.nih.gov/
rindex/dbaccess/ldgde/p4.  Antiretroviral therapy
is individualized and based on informed deci-
sions made by the treating physician and the
patient. In other words, there are no set CD4
numbers or virus load values that automatically
trigger or preclude antiretroviral therapy.
Administering and Monitoring HAART
The TDCJ Pharmacy and Therapeutics (P & T)
Committee have developed policies regarding
the administration and continuation of antiretro-
viral drugs.  In recent years, the director of the
AIDS Care and Clinical Research Program has
been appointed to this committee which has
allowed the input of treating physicians to shape
policy.  Several P & T policies affect the use of
antiretroviral medication administration. The poli-
cies are as follows:
1. All antiretroviral agents are included
on the TDCJ Formulary; new agents
are usually approved for addition to
the formulary within a month of receiv-
ing FDA approval.  
2. Combination therapy that includes a
protease inhibitor or nonnucleoside
reverse transcriptase inhibitor is con-
sidered standard and is distributed by
directly administered therapy (DAT)
multiple times per day at pill windows.
Monthly pharmacy computer reports
are monitored and if an offender is
found to be on suboptimal therapy
(dual or single nucleosides), the phar-
macy notifies a unit-based provider,
who is asked to correct or justify the
suboptimal therapy.  
3. A 10-day supply of medication is
dispensed at release from prison and
Texas AIDS Drug Assistance Program
(ADAP) papers are completed and
submitted by pharmacy personnel at
release. The offender is given the
responsibility of obtaining the medica-
tions by calling the ADAP program toll-
free number and designating a phar-
macy for dispensing of drugs.
4. Finally, an antiretroviral medication
discontinuation policy has been imple-
mented in which 80% of the scheduled
doses of each antiretroviral medica-
tion must be taken in order for the
offender to continue treatment.  
Adherence 
Adherence is documented by Certified
Medication Aids (CMAs) who enter this data on
the pharmacy computer system as they distrib-
ute medications to offenders at "pill windows" at
the correctional units.  Pharmacy personnel
review adherence data every month.  When an
offender’s adherence on any antiretroviral med-
ication falls below 80 %, a unit-based provider is
notified and asked to perform adherence coun-
seling. During counseling, the offender is
assessed for conditions that impair adherence:
medication side effects, unreasonable medica-
tion combinations, and the occurrence of other
activities (work, meals, school) scheduled simul-
taneously with pill window times.  The medica-
tion discontinuation policy is also reviewed with
the offender.  Necessary adjustments are made
to the antiretroviral regimen or related medica-
tions in order to minimize non-adherence due to
drug side effects.  When possible, daily routines
are altered or medication passes are given so
that non-adherence due to conflicting events is
minimal. After 30 days, adherence is reassessed.
If adherence remains below 80%, antiretroviral
therapy is discontinued. The offender has the
opportunity to resume antiretroviral therapy after
a 90-day hiatus.
Upon initial review, the antiretroviral medication
discontinuation policy seems unduly harsh
and/or paternalistic. However, if one considers
that poor adherence not only leads to drug-resis-
tant virus which impairs treatment response for
the individual, but may also lead to transmission
of drug-resistant virus within and outside of the
prison, this policy is beneficial to the individual
who may accept effective therapy in the future
and beneficial to the public health by reducing
the incidence of treatment-resistant HIV infection.
Challenges and Solutions
Initially, our HIV clinic was at UTMB at
Galveston, which made it difficult to provide opti-
mal HIV care due to distance, staffing, and sep-
aration of care from the offender’s home unit.
Therefore, a Center for Excellence in HIV Care
was established at the maximum security Stiles
Unit in Beaumont, Texas is approximately 85
miles from Galveston.  Currently 1,200 HIV pos-
itive men of various security designations are
housed there.  Security regulations were modi-
fied at this unit so that offenders with different
security designations can be housed together in
specified quarters that are centered around
health care delivery areas where clinic and pill
windows are located.  The trip to UTMB takes a
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Managing HIV Care in a Large State System - Texas 
Continued from page 1
Table 1.  Fiscal Year 2000 Projected Budget Figures for TDCJ
Health Care Entity TDCJ Correctional Managed Care* TDCJ Pharmacy Services
Total Budget $268,000,000 $26,250,633
HIV-Related Spending $41,400,000 $12,368,250
HIV-Related % of Total 6.5 47.1
Table 2. TDCJ HIV Testing Results, by Year
Year 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 to
8/31/99
# of Offenders
Tested
7192 7395 9310 16,634 16,241 21,549 25,721 29,024 49,114 37,807
# of Positive Tests 415 485 459 615 616 702 549 691 971 606
% Positive 5.7 6.6 4.9 3.7 3.8 3.3 2.1 2.4 2.0 1.6
Table 3.  CDC Classification of TDCJ Offenders, 1999
CDC Classification Men Women Total (%)
A1, A2 (asymptomatic) 1072 200 1272 (50.2)
B1, B2 (symptomatic) 237 22 259 (10.2)
A3, B3, C1-3 (AIDS) 932 70 1002 (39.6)
Total (%) 2241 (88.5) 292 (11.5 %) 2533 (100)
*exclusive of Psychiatric Care Costs
(Table made possible through personal communication, Alan Sapp, Assistant Director for
Administrative Services, Texas Correctional Managed Health Care Committee)
(Table 2 and 3 are from the Texas Department of Criminal Justice Health Services Division Inter-
Office Communication from Scott L. Samford, PHT-III, HIV Program Coordinator, August 31, 1999) Continued on page 5
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Dear Colleagues,
October, a busy time for all, was exceptionally busy for HEPP, the HIV Education Prison Project at Brown
University, due to preparations for our conference on Clinical Trials in Correctional Settings. Most of you probably
thought we dropped off the face of the earth! Please accept our apology for two late issues in a row. We pledge to
get the Newsletter back on track (faxed during the second week of the month) by the December issue. In this issue
of HEPP News, we are pleased to bring you reports on HIV care in four major correctional facilities across the
nation.  The main article, by Dr. David Paar, describes in detail how the Texas Criminal Justice Department, a very
large state system, provides HIV care.  We also include another succinct update from ICAAC by Dr. Joe Bick, of
the California DOC. This month’s HIV 101 provides a list of routine vaccinations for HIV infected persons.  After
reading this issue, clinicians should be able to identify which vaccines to administer to HIV infected patients and to
understand current debates about discontinuing prophylaxis for opportunistic infections.
And now for a quick report on our Clinical Trials meeting. Correctional medical experts, legal experts, ethicists, and
prisoner advocates gathered in Providence on October 13, 14, and 15 to review the history, legal and ethical
aspects, and medical conduct of clinical trials in correctional settings and to propose expanded guidelines which
may enable inmates and their medical providers to have access to experimental therapies, while protecting
inmates from potential abuses of clinical research. 
HEPP editor Dr. Rick Altice (Yale HIV/Prison Project), Dr. Al Novick (Yale Center for Interdisciplinary Studies on
AIDS), and Dr. David Thomas (Florida DOC) helped HEPP and the Brown AIDS Program (BRUNAP) organize the
conference. Additional organizers included Drs. David Wohl and Becky Stevenson of U. North Carolina (and the
NC DOC), Dr. David Paar of Texas UTMB and DOC, Dr. Joe Bick of California DOC, Betty Ryder of the NC DOC,
Ned Heltzer of PHS, Dr. Lou Tripoli of CMS (central office) and Dr. Ken Mayer of Brown University. 
During the course of the conference, participants learned that inmates currently do participate in clinical trials in a
number of correctional institutions. In Texas, for example, the close association between the University of Texas
medical programs and corrections has enabled inmate participation in a wide range of trials of anti-retroviral agents.
In Florida, clinical studies have been carried out at the Central Florida Receiving Facility South Unit under the direc-
tion of the University of Miami AIDS Clinical Trials Group (ACTG). In North Carolina, clinical research studies have
also been conducted, however that research is currently limited to studies unique to the prison setting, such as the
efficacy of Directly Observed Therapy (DOT) versus Self-Carry Therapy (SCT). 
Conference participants heard nationally recognized ethicist Nancy Dubler and a federal delegate from the Office
for Protection from Research Risk, Jeffrey Cohen, expound on the participation of prisoners in research trials.
Highlights of the conference also included presentations by Dr. Margaret Fischl (U. Miami) and Dr. Rich Pollard (U.
Texas Medical Branch at Galveston). The latter half of the conference was devoted to discussions by "working
groups" that included former inmates, prisoner advocates, ethicists, lawyers, correctional representatives, and cor-
rectional physicians. These groups conducted open discussions on four topics: who should conduct trials, what
type of correctional setting would be appropriate for trials, what type of research should be allowed in correctional
settings, and whether coercion and undue influence were factors influencing prisoner participation in research.
Following these discussions, a small group of 16 experts and 20 observers met in a closed session to report on
issues raised by the working groups and to begin the process of formulating more detailed guidelines for the con-
duct of clinical trials in correctional settings. 
In general, participants at the conference and members of the closed panel appeared to agree that prisoners
should not be denied access to clinical trials in correctional settings.  Due to concerns about prisoner vulnerability
to coercion and undue influence, however, it was also agreed that the setting for the trial should conform to certain
standards and that the conditions at the site should be monitored on a regular basis. Participants who were in favor
of allowing prisoners access to clinical trials, were also in favor of restricting trials to locations where "good clinical
practice" was in place or where good clinical care would be independently introduced before a clinical trial would
begin, so that prisoners would not be restricted to participating in a clinical trial in order to obtain decent medical
care. One interesting proposal was that a clinical trials review committee specifically formed for correctional trials
should be established at the national level (similar to existing groups that accredit prisons, or prison hospitals). The
committee would be responsible for carefully reviewing each trial proposed for a correctional setting and monitor-
ing the trial site for compliance with the criteria to be set forth in the guidelines. 
Overall, conference participants reported feeling that they were present at a momentous event, which was one of
the first national meetings on the topic of clinical trials in correctional settings to be convened in greater than 20
years. Many different perspectives were voiced during the course of the meeting, and additional perspectives will
be gathered before the proposed guidelines are published. Conference organizers hope that this meeting will even-
tually lead to the development of guidelines that will protect prisoners from research abuses while preserving their
access to clinical trials. A full report on the closed panel discussions and a set of expanded guidelines for clinical
trials in correctional settings will be published in two to three months - and you can be sure, as a HEPP subscriber,
that you’ll hear about the guidelines first! 
Lastly, I want to mention that I enjoyed meeting many of you at the National Conference on Correctional Health
Care in Fort Lauderdale this month. I appreciated the positive feedback you gave me on HEPP News, and I encour-
age you to continue to send us your comments and suggestions. Don’t forget to check out the website at
http://www.HIVCorrections.org.
Sincerely,
Anne S. DeGroot, MD
L E T T E R F R O M T H E E D I T O R
Patient Access to Care
California Medical Facility (CMF), Vacaville CA
Joe Bick, MD
Chief Medical Officer, HIV Treatment, California Medical
Facility, Vacaville, CA, 
Speaker’s Bureau: Agouron, Bristol-Myers Squibb
California Medical Facility (CMF) has the largest HIV
treatment program in the California Department of
Corrections (CDoC), providing comprehensive care
to 500 men. Each physician in the outpatient setting
has responsibility for approximately 160 HIV infected
patients.  An additional physician is responsible for
the hospice and supported living units, and three
provide care in the hospital.
Fundamental to the success of this program is an
organizational structure that allows one individual to
supervise all aspects of the HIV treatment unit.  In
the ever-changing and unpredictable environment of
corrections, this type of authority is crucial if a pro-
gram is to rapidly adapt to obstacles (lockdowns,
correctional policy changes, etc.).
Patients initiate a clinic visit by submitting a request
for services.  These requests are triaged by the nurs-
ing staff, who then schedule patients to be seen.
There is a physician on site 24 hours a day seven
days a week to handle emergencies.  For routine
requests, patients may wait 1 to 14 days to be seen.
Patients can self refer to mental health, dentistry,
optometry, and podiatry. All other consultations are
physician generated.  Patients are seen on average
once a month. Although patients can refuse medical
care, an effort is made to ensure that all patients are
seen at least once every three months.  
Provider and Peer Education
Florida Department of Corrections
Bert Hurowitz, MD
There are two important components to the HIV
Care program at the Florida Department of
Corrections: our peer education program, and our
provider education program.  The programs begin
once we have found an inmate is seropositive.
Treatment of newly diagnosed inmates and those
who self identify as HIV infected is dependent upon
the stage of the disease, prior treatment, past histo-
ry of opportunistic infections, co-morbidities, and
especially the desires of the inmate.  We take the
patients’ own readiness into account, since we can-
not mandate HIV therapy, and we recognize that we
obtain maximal adherence when we have the full
commitment of the patient. To facilitate and encour-
age adherence, we have established inmate to
inmate (peer) education groups and a health care
team to provide additional HIV education.
Because we have found it difficult to provide all of
these services at every institution, we have elected
to re-structure our facilities so that treatment for
HIV/AIDS will occur at selected sites. By the time we
finish restructuring, HIV infected inmates who are on
treatment will be located in selected institutions, rep-
resenting less than a third of our over sixty institu-
tions.  Two institutions will provide the highest level
of care and the remainder of the institutions will pro-
vide the type of care that is usually provided in out-
patient HIV clinics in the community. All of the practi-
tioners at the HIV facilities will be "experts" in the
care of this infection. 
To educate and update the practitioners, we have
developed a unique educational program. Similar to
the program in Texas, we have been operating a
"mini-HIV residency" at the HIV specialty institutions
over the past two years.  The program is a one-week
total immersion course concerning HIV/AIDS and
closely associated subjects, such as tuberculosis,
hepatitis, and special women’s concerns.  This
course is both didactic and clinical. The "students"
have direct hands-on experience.  They review case
histories and examine patients who have many of
the conditions discussed during the course.  The fac-
ulty consists of experts from both inside and outside
of the Florida DOC.  In addition to the mini-residen-
cy, we present updates on HIV/AIDS treatments at
our monthly staff meetings. Last year we devoted
eight hours of our yearly staff workshop to lectures
on HIV and AIDS.  
Finally, we have offered inmates the opportunity to
volunteer for investigational treatment programs
through collaboration with the University of Miami.
These programs give our staff opportunities to be
part of "state of the art" treatment protocols and they
offer our patients access to the newest treatment
HIV Care in New Jersey State Prisons
Sheree Starrett, MD
Speakers Bureau: Roxane, Merck, Bristol-Myers Squibb, Glaxo
Wellcome
The current goal of the HIV program in NJ is to try to
provide the best possible services at our local sites.
To accomplish this goal, a statewide HIV advisory
panel was created to include the NJ correctional
physicians most skilled in HIV care.  This group of
eight physicians meets quarterly to discuss various
HIV issues. Four outside HIV physician experts also
attend these meetings, providing us with even more
knowledge on how best to care for HIV infected
inmates.
By court order, we are not allowed to segregate HIV
patients for any reason, and therefore are unable to
follow the Florida model of creating "centers of excel-
lence."  Some of our sites may have as few as 3 or
4 patients, while larger sites will have 100 + inmates.
We have seen a dramatic decline in all HIV morbid-
ity and mortality, presumably relating to the use of
effective antiviral therapy.
As previously stated, we try to provide all care at the
local sites.  All patients are managed by members of
the HIV advisory panel or by health care providers
(physicians or NPs) under their immediate supervi-
sion.  Many sites have Infection Control Nurses, who
are also very active in patient care. Patients are gen-
erally treated according to the DHHS and IAS guide-
lines. Patients are seen at least quarterly and more
frequently at the discretion of the caregiver. Lab
work, including CD4 count and ultrasensitive viral
loads are done every 3 months and whenever ther-
apy changes require repeat testing. All FDA-
approved antivirals are available to inmates.
Medications are provided in monthly quantities from
a wholesale pharmacy. Monitoring of patient adher-
ence is problematic. Withdrawal of therapy from per-
sistently nonadherent patients is at the discretion of
the provider. Patients are not charged any co-pay for
HIV services, except for medications. This fee is
$1.00 for every 90-day prescription, (i.e. 90 days of
nelfinavir for $1.00). No patient is denied care based
on inability to pay. 
Patient outcomes have improved tremendously
throughout the state in recent years.  The number of
AIDS related deaths in NJ declined from 74 in 1996
to 17 in 1998. Hospital admissions and lengths of
stay have shown the same trends. The key to our
success has been the major effort devoted to staff
education and with that, the widespread usage of
highly active antiviral therapy. 
Despite all our successes, we need to improve our
patient education and discharge planning programs.
Because of a high rate of nursing and medical staff
turnover, we have to continually work on developing
the skill levels of new staff members. We also need
to work on educating the general prison population
as well as the custody staff.  Many prisoners must
not only deal with the issues of having a difficult dis-
ease, but also with all the stigmas related to this dis-
ease. Improving the knowledge of all the inmates
and custody personnel might help alleviate this prob-
lem.  Lastly, we need to try to develop more effective
discharge planning and linkages with the outside
community. I feel that without this essential last step,
many of our efforts are lost upon prison release.
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Spotlight: California, Florida, and New Jersey Correctional HIV Care
For this spotlight on correctional HIV care, HEPP staff asked physicians from the departments of corrections from California, Florida and New Jersey
to outline the HIV care programs at their institutions. We asked them to include what they consider the best aspects of their programs, as well as what
they might change.  Their reports are summarized in the table below, followed by their own words.
California Medical
Facility (CMF),
Vacaville CA
(Mens)
Florida Department
of Corrections
New Jersey Texas Department of
Criminal Justice
Type of Care DOC DOC Subcontracts DOC
Location of Care On-site. Contract to
local hospitals for
critical care.
Centralized On-site. Contract to
local hospitals for
critical care.
Centralized
Testing Voluntary Voluntary Voluntary Voluntary
Seroprevalence
(HIV+)
2.5% (4500) Men1
~500 at CMF
3.2% (1929) Men
6.8% (223) Women11
3-4% (900) Men
10% (100) Women
1.3% (1,645) Men
2.3% (231) Women11
Medication
Distribution
directly observed
therapy (DOT) or
keep on person
(KOP)
DOT, except >bid
or those with
special food
requirements,
which are
KOP/weekly
DOT Varies from site to
site: DOT or KOP
DOT
Peer Education
Programs
Yes (Vacaville) Yes (Central Florida
Receiving Center)
Yes, depending on
site
Outside prevention
education group
comes intermittently
Discharge
Planning
Social worker is
assigned to each
patient.  Patient is
contracted to
transitional
programs and
providers.
Patient directly linked
to a treatment facility
in the community into
which the patient will
be discharged
Given 2 weeks of
medication,
encouraged to seek
assistance at PH
clinics
Given 10 days of
medication,
encouraged to call the
AIDS Drug Assistance
Program (ADAP)
This is the %(number) of HIV seroprevalence in the entire California Department of Corrections
Source:  Hammett TM, Maruschak LM.  1996-1997 Update: HIV/AIDS, STDs, and TB in Correctional Facilities.  U.S.
Department of Justice, Office of Justice Programs, National Institute of Justice. July 1999.  NCJ 176344.
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couple of hours and offenders return to Stiles the same day asr their
UTMB appointment.  One of the Galveston ACCRP Physicians travels to
the Stiles Unit one-day every other week to see patients and to consult
with unit-based physician assistants who have reviewed medical and anti-
retroviral history on patients who are failing therapy and need to have
medications changed.  Similarly, the minimum security Texas City
Women’s Sheltered Housing Unit, only 15 miles from UTMB Galveston,
houses minimum security female offenders with HIV infection.  Another
ACCRP AIDS specialist travels to Texas City every other week to see the
offenders housed there and to see HIV positive female offenders who are
transported to Texas City from other units of assignment.  
Minifellowships for Better Providers
In order to provide HIV care training to Unit-Based Providers as well as to
foster a mutually respectful relationship between the Galveston Specialists
and the Unit-Based Providers, a three day "HIV Minifellowship for
Correctional Care Providers" (18 category 1 CME hours) was developed
and is conducted three times per year for 10 - 15 Unit-Based Providers per
session. We need to establish a working relationship with 61 physicians,
73 mid-level providers, and 71 Chronic Infectious Diseases (CID) nurses
in the TDCJ units in the Eastern Region.  Although the course is intensive
and consumes three eight hour days, having Galveston HIV Specialists
serve as faculty as well as participate in evening recreational activities with
the Unit-Based Providers has facilitated an appreciation for each others’
roles and has definitely enhanced communication regarding HIV care of
offenders between the units and Galveston.  
Teleconsults
Unit providers who have completed the minifellowship and Galveston
Specialists consult with one another regularly by telephone or by means
of telemedicine video equipment - thus a system of communication and
care delivery called "teleconsults" is evolving.  Patient cases are summa-
rized on data sheets and faxed to the Galveston HIV Specialist prior to the
teleconsult session.  During the session, the patient’s course is discussed
and revised treatment plans are developed.  Twice weekly telemedicine
clinics were developed and are being refined so that a Galveston special-
ist can use state of the art electronic equipment to evaluate inmates at
remote sites across the state. To make telemedicine work, unit level labo-
ratory capabilities had to be expanded so that viral loads and other tests
could be performed there instead of UTMB Galveston.
Summary
The large geographic expanse of Texas and the sheer number of HIV pos-
itive offenders within the TDCJ are primary forces that made it necessary
to change from a centralized HIV Health Care System based at UTMB
Galveston to a cooperative system in which HIV Health Care responsibil-
ities are shared by providers at the units.  A uniform HIV-Specific Infection
Control Policy, along with several Pharmacy and Therapeutics Committee
Policies regarding antiretroviral medications, provided a foundation for this
shared health care, but was not enough, by itself, to facilitate the transi-
tion.  A three day "HIV Minifellowship for Correctional Care Providers" not
only prepares unit-based providers to assume additional responsibility for
HIV Health Care, but also facilitates a cordial working relationship
between the Galveston HIV specialists and Unit-Based Providers.
Telemedicine clinics have permitted UTMB Galveston HIV Specialists to
evaluate offenders while they remain at remote sites throughout Texas,
and a budding "teleconsult" clinic have enhanced efficiency without
impeding quality of care.  Finally, unit-based laboratory capabilities, in par-
ticular, the ability to collect and process viral load specimens were expand-
ed in order to meet the needs of unit-based, specialty-driven, HIV care.
The role of the CID nurse is being evaluated and hopefully, will be modi-
fied to become a crucial link between the units and UTMB Galveston.  It
has been useful to recognize that the analysis and revision of our HIV care
delivery programs in a geographically large and populous institution like
TDCJ is a process that moves slowly, but ultimately leads to more efficient
delivery of quality health care.
References:
1.Hammett, TM. Maruschak LM. 1996-1997 Update: HIV/AIDS, STDs,
and TB in Correctional Facilities.  U.S. Department of Justice.  July 1999.
NCJ 176344.
2.Personal communication, Alan Sapp, Assistant Director for
Administrative Services, Texas Correctional Managed Health Care
Committee. 1999.
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HEPPigram A feature of HEPP News providing concise solutions to correctional HIV-related problems.
ICAAC Highlights Part II: Opportunistic Infections
by Joe Bick, MD
Speakers Bureau: Bristol-Myers Squibb, Consultant: Agouron, BMS
The 39th annual Interscience Conference on Antimicrobial Agents in Chemotherapy (ICAAC) was held in San Francisco in
September. Last month, HEPP News provided a review of HAART trial reports and HIV resistence testing. This month’s report will
discuss discontinuation of prophylaxis for opportunistic infections (OIs).
As increasing numbers of patients experience dramatic increases in their CD4 counts due to highly active antiretroviral therapy
(HAART), the question is raised as to if and when OI prophylaxis can be discontinued. Specifically, if an individual at one time had
a CD4 count low enough to put them at risk for a particular OI but subsequently had an increase in CD4 to a level above the risk
threshold, can preventative therapies be discontinued? Does the increase in CD4 count necessarily represent immune reconstitu-
tion? If so, has the individual’s immune system retained the ability to recognize the OI in question? Several abstracts were presented
that attempt to answer these questions for Pneumocystis carinii (PCP), and Mycobacterium avium (MAC).
PCP: Abstract 1165 was an Italian study of 600 patients receiving PCP prophylaxis because of a past CD4 count <200 who subse-
quently had a CD4 rise to >200. PCP prophylaxis was discontinued in all patients. During a median follow-up of 6.2 months, there
were no cases of PCP. A second study involving PCP prophylaxis was late breaker #24 from Spain. In this study of 488 patients,
half were randomized to continue prophylaxis and half to discontinue it. After 11.3 months of follow-up, no cases of PCP developed
in either group.
MAC: Late breaker abstract #23 examined 643 patients who were on MAC prophylaxis because of previous CD4 counts of <50 who
now had CD4 counts >100. These patients were randomized to receive either weekly azithromycin or no MAC prophylaxis. In all,
there were only two cases of MAC, both in the untreated group. Further supporting the discontinuation of prophylaxis was abstract
#1164, which demonstrated that within six weeks of beginning a macrolide for MAC prophylaxis, the respiratory flora is all resistant
to macrolides. This could potentially make treatment of subsequent respiratory illnesses more problematic. It should be noted that
the above abstracts address discontinuation of primary MAC prophylaxis, which is not the same as stopping therapy in those with
past documented MAC disease.
The above data adds to the growing consensus that it may be appropriate to discontinue primary prophylaxis for MAC and PCP in
those who who have experienced a reconstitution of their immune systems as manifest by a rise in CD4 count to >200 for PCP and
>100 for MAC. The data is not clear concerning those with prior PCP, nor is it clear that treatment for MAC can be stopped in those
with rising CD4 counts.
In spite of this enouraging information, I believe that in the correctional setting the decision to discontinue primary prophylaxis for
PCP should not be made lightly. Many incarcerated patients fail to follow-up medically following their parole. If a patient is not like-
ly to obtain regular CD4 counts, the risk associated with continuing PCP prophylaxis is less than that of experiencing immune dete-
rioration and subsequently developing PCP. Depending upon the patient, it might be most prudent to encourage continuation of pro-
phylaxis regardless of CD4 count. Keep in mind that bactrim may also help prevent otisis, sinusitus, and other respiratory illnesses.
S A V E T H E D A T E S
Management of HIV/AIDS in the Correctional
Setting:  A Live Satellite Videoconference Series
"Hematologic Complications of HIV Infection"
January 18, 2000, 12:30-3:30 pm EST
Phone: 518.262.4674, or e-mail kinerc@mail.amc.edu 
Site registration is mandatory, and must be done no
later than one week before the broadcast.
CME credit is available.
Retroconference 2000 7th Conference 
January 30-February 2, 2000 San Francisco, CA
Registration opens: November 30, 1999
Late breaker abstract deadline: January 5, 2000
More information available at: http://www.retrocon-
ference.org/
15th Annual Rocky Mountain Regional
Conference on HIV Disease
February 18 - 19, 2000
Denver, CO
Email: cap@coloaids.org
URL: http://www.coloaids.org
Phone: 303.837.0166; Fax: 303.837.9213
CME available.
Maj Des: Antiviral drugs, Correctional facilities,
Cultural factors, Hepatitis, HIV prevention, HIV
transmission, HIV/AIDS education needs. 
Ryan White CARE Act All-Title National Meeting
Making a Difference: HRSA’s HIV/AIDS
Programs
January 18- 21, 2000
Washington, DC
Phone: 202.887.0620 x14
Sponsors: Health Resources & Services
Administration (HRSA)
Infectious Diseases 2000
January 28 - 30, 2000
Miami, FL
Email: conferences@arhp.org
URL: http://www.arhp.org/arhpframeconf.html
Phone: 202.466.3825 or 877.444.ARHP; 
Fax: 202.466.3826
Sponsors: Association of Reproductive Health
Professionals (ARHP)
Maj Des: Hepatitis, Hepatitis prevention, HIV posi-
tive persons, Human papillomavirus (HPV),
Infection control, Infections, Sexually transmitted
diseases (STDs), Tuberculosis (TB), Women,
Womens health services. 
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Anti-HIV Treatment Improves Immune
System and Fights CMV
A new combination of HAART appears to pre-
vent the progression of cytomegalovirus
(CMV) retinitis.  Researchers at the NIH
found that all 14 patients with CMV retinitis
enrolled in the study who took HAART were
able to cease their standard anti-CMV med-
ications safely and without progression of
CMV.  Although the study focused on CMV
retinitis, the results may be a "gateway" for
researchers in treating other opportunistic
infections, such as Mycobacterium avium
complex  (MAC), which also can be controlled
by HAART alone, according to preliminary
results from NIAID-supported trials. 
(NIH News Release, 11/2/99.  JAMA 1999;
282(17):1633-1637.)
Vaccine Combination for HIV
Two experimental vaccines taken together
are safe and have induced anti-HIV immune
responses in the majority of volunteers
enrolled in Phase II clinical trials sponsored
by the National Institute of Allergy and
Infectious Diseases. The trial, called AVEG
202/HIVNET 014, was designed to test
ALVAC-HIV vCP205, which stimulates cellu-
lar immunity and ramps up T-cell activity, and
SF-2 rgp120, which stimulates the production
of HIV neutralizing antibodies. These prelimi-
nary data do not prove that the vaccine is
effective against HIV infection, since the trial
was neither large enough nor long enough to
draw conclusions (NIAID press release,
7/13).  
For more information, see the HIVNET web-
site:http://www.niaid.nih.gov/daids/hivnet.htm
HIV Rebounds after Cessation of Therapy
In a recent Nature article, Anthony Fauci, MD,
and Tae-Wook Chun, PhD et al published
findings that the viral load in two of their
patients rebounded after HAART and inter-
leukin-2 (IL-2) were stopped. The two
patients were treated with HAART for 33 and
30 months.  Both patients also had received
intermittent intravenous infusions of IL-2 for
42 and 50 months.  HIV plasma levels were
below 50 copies/mL before treatment was
stopped.  The replenishing of the virus seen
in these two patients may be due to viral
reservoirs that hide from even the most
potent HAART regimens. This data supports
the findings of recent reports that suggest
eradicating HIV from the body with currently
available HIV treatments is unlikely because
the virus remain undetected in sanctuaries
that drugs cannot access, and can exist in
latent forms on which the drugs have no
effect. (NIH News Release, 10/27/99.  
More info. available at http://www.niaid.nih.gov.
News Flashes 
Subscribe to HIV Inside
A new quarterly newsletter addressing HIV-management issues specific to correctional care.
If you are interested in receiving this free publication, please fill out the form below.  In addition to receiving HIV Inside, this con-
tact information will be entered into an HIV-management database, allowing additional education materials to be forwarded.
Name ________________________________________________________________________________________
Title ________________________________________________________________________________________
Agency/Facility ________________________________________________________________________________
Address________________________________________________________________________
City ______________________________________________ State ______________________ Zip __________
Phone ____________________________________________ Fax ______________________________________
Fax back to Brendan Maney at World Health CME at 212.481.8534
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IV
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1 Routine Vaccinations for HIV-Infected Adults
The following vaccines are recommended for HIV-Infected persons.  Inactivated or subunit vaccines pose no additional risk of adverse events
and should be considered part of  routine health maintenance for these individuals. In some cases, viral load may increase slightly after an immu-
nization.  Such increases, however, appear to be transient, and their clinical significance is unknown.  
Adapted from Barlett JG. The Johns Hopkins Hospital 1998-1999 guide to medical care of patients with HIV infection.  Eighth edition. Williams
& Wilkins, Baltimore MD 1999. 55-7;  and  Merigan TC, Bartlett JG, and Bolognesi D.  Textbook of AIDS Medicine, Second Edition. Williams &
Wilkins, Baltimore, MD. 1999. 322.  Further informed by the Immunization Action Coalition, 651/647.9009.
Website at:  http://www.immunize.org/catg.d/p2011b.htm
Vaccine Indication Regimen Comments
Pneumococcal
vaccine
All HIV patients, once
every ten years
0.5 mL IM Risk of S. pneumoiae infection is increased 100-fold.
Efficacy of vaccine is best when CD4 count is >200.
Revaccinate if CD4 was <200 before HAART and is
>200 6 months after the first vaccine.
Influenza
vaccine
All HIV patients yearly
in Oct-Dec, during the
flu season
0.5 mL IM Risk of influenza is not clearly increased, but
prevention may avoid expensive and complicated
diagnostic evaluation of flu-like complaints, and may
reduce transmission of flu in correctional settings.
Vaccination may increase HIV viral burden, but
natural flu infection may increase it more.
Haemophilus
influenza B
vaccine
Not recommended 0.5 mg IM x1 Not recommended because most infections with H.
Influenzae  in HIV-infected persons involve non-
typeable strains that are not included in the vaccine
(JAMA 1992;268:3350).
Hepatitis B
vaccine
See Comments 3 IM doses at 0, 1, and
6 mo.
Alternate dose timing:
0, 2, 4 mo; or 0, 1, 4
mo.
Recombivax: 10 µg
Energix: 20 µg
CDC Indications: Members of high risk groups*,
inmates of long term correctional facilities,
seronegative IDU, sexually active gay men,
heterosexual men and women with STD or >1 sex
partner in past 6 mo and household or sex contacts
of HBsAg carriers.
Screening test is anti-HBc.
Risk of becoming HBsAg carrier is increased with HIV
infection.
CDC recommends measurement of antibody response
in HIV infected patients at 1-6 months after 3rd dose;
non-responders should receive 1-3 boosters.
Note that funds for immunizing patients <18 years may
be available from local Health Departments.
Inactivated
polio vaccine
(eIPV)
Those without prior
immunization, one
time only adult
booster.
0.5 mL subcutaneously Preferred for HIV-infected persons and close contacts.
Polio has been eliminated from the Western
hemisphere.
Hepatitis A
vaccine
Men who have sex
with men, illicite drug
users, people with
chronic liver disease,
especially HCV
1 mL adult formulation
intramuscularly x1 ‡14
Havrix was FDA approved in 1995 and may be used in
place of immune globulin.
Serologic tests show 30% of adults are protected by
prior infection.
Tetanus-
diptheria (Td)
All adultsbooster q
10 yrs
0.5 mg IM HIV infection is not a contraindication.
Live Attenuated Vaccines
Vaccine Indications
Bacille Calmette-GuØrin (BCG) vaccine Contraindicated
Oral poliomyletis vaccine Contraindicated
(eIPV preferred)
Varicella-zoster vaccine Contraindicated (if HIV-infected person is seronegativeavoid
contact with chicken pox and zoster and vaccinate susceptible
close contacts).
Measles, mumps, rubella (MMR) vaccine Contraindicated
* High Risk groups include: household contacts and sex partners of HBsAg-positive persons; users of illicit injectable drugs; heterosexuals with
more than one sex partner in 6 months; men who have sex with men; people with recently diagnosed STDs; patients in hemodialysis units and
patients with renal disease that may result in dialysis; recipients of certain blood products; health care workers and public safety workers who
are exposed to blood; clients and staff of institutions for the developmentally disabled, and certain international travelers.
Inactive or Subunit Vaccines
Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians
Recognition Award.  To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each
of the questions. A minimum of 70% of the questions must be answered correctly.  This activity is eligible for CME credit through
December 31, 1999.  The estimated time for completion of this activity is one hour and there is no fee for participation in this activity.
1. Which of the following vaccines are recommended for HIV-
infected inmates? (more than one may be correct). 
a) Haemophilus influenza B vaccine
b) Hepatitis B vaccine
c) BCG vaccine
d) Oral poliomelitis
e) MMR vaccine
2. At intake, an HIV infected inmate has revealed a history of illicit
drug use and reports that one of the children in his household just
had chickenpox.  He also has not had his TD shot in 12 years.
Which vaccine or vaccines would you recommend? (more than
one may be correct) 
a) Hepatitis B vaccine
b) Tetanus-diptheria
c) Varicella-zoster vaccine
d) Measles, mumps, rubella (MMR) vaccine
e) HBV
3. Which of the following statements is false?
a) Vaccination may increase HIV viral burden, but natural
flu infection may increase it more.
b) Haemophilus influenza B vaccine is not recommended
because most infections with H. Influenzae in HIV-infected
persons involve non-typeable strains that are not included
in the vaccine.
c) Pneumococcal vaccines should not be given again even
if CD4 was <200 before HAART and is >200 6 months after
the first vaccine.
d) Risk of becoming HBsAg carrier is increased with HIV
infection.
e) HIV infection is not a contraindication for tetatnus dipthe-
ria vaccine.
4. In which of the following states are HIV/AIDS investigators cur-
rently conducting clinical trials?
a) Texas and Georgia
b) Massachusetts and California
c) New York State and North Carolina
d) Florida and Texas
e) Maryland and New York
5. Clinicians are now considering it possible to discontinue
Mycobacterium Avium prophylaxis when the patient is responding
to HAART and their CD4 T cell count has been
a) over 50 for two months
b) over 200 for two months
c) over 100 for six months
d) over 200 for six months
e) over 500 for two months
6.   Which of the following statements is false?
a) Recent studies have shown that discontinuing PCP pro-
phylaxis does not increases chances of developing PCP
within 6 months after stopping treatment.
b) Recent studies on PCP have shown that discontinuing
PCP prophylaxis is recommended even if the patient has a
prior history of PCP infection.
c) Risk of becoming HBsAg carrier is increased with HIV
infection.
d) Researchers have found that 14 patients with CMV
retinitis who were taking HAART were able to cease stan-
dard anti-CMV medication without progression of CMV.
BROWN UNIVERSITY SCHOOL OF MEDICINE  OFFICE OF CONTINUING MEDICAL EDUCATION  BOX G-A2  PROVIDENCE, RI 02912
The Brown University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continu-
ing medical education activities for physicians.  This activity has been planned and implemented in accordance with the Essentials and Standards
of the ACCME.
The use of the Brown University School of Medicine name implies review of the educational format and material only.  The opinions, recommenda-
tions and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the
Brown University School of Medicine.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660
Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
main article 5  4  3  2  1   5  4  3  2  1   
secondary 5  4  3  2  1   5  4  3  2  1   
article
HEPPigram 5  4  3  2  1   5  4  3  2  1   
updates 5  4  3  2  1   5  4  3  2  1   
save the date 5  4  3  2  1   5  4  3  2  1   
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
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